Postmarketing Drug Safety Evaluations

What is FDA Posting? Why is FDA posting this summary information? What information is provided on this web site? What information does FDA consider for these postmarketing safety evaluations? How is the information analyzed? Postmarketing Drug Safety Evaluation Summaries October 2010 – December 2010 January 2010 – September 2010    What is FDA posting? This…

Minutes from Stakeholder Meeting on MDUFA III Reauthorization, April 27, 2011

Stakeholder Meeting on MDUFA III ReauthorizationApril 27, 2011, 1:30 – 3:30 PMHHS Humphrey Building, Washington, DCRoom 305A Purpose To discuss FDA’s proposal package presented to Industry for MDUFA III. Participants Meeting Start Time: 1:45 pm Background FDA recently presented a proposal package for MDUFA III to Industry. The goal of the package is to achieve…

Agenda and Materials From May 4, 2011 FDA MDUFMA / MDUFA Performance Report (PDF)

%PDF-1.6% 1344 0 obj/Names 6729 0 R/Outlines 128 0 R/Metadata 1341 0 R/Pages 1337 0 R/OCProperties/OCGs[1345 0 R]/StructTreeRoot 5402 0 R/Type/Catalog/Lang(EN-US)endobj6729 0 objendobj128 0 objendobj1341 0 objstream 2011-05-10T12:16:25-04:002011-05-03T11:58:07-04:002011-05-10T12:16:25-04:00Adobe Acrobat 8.2 Combine Filesapplication/pdf — DRAFT — JGN uuid:55de30d2-744a-4e94-b2da-9110d4f42dd6uuid:e07e6d11-3241-4f44-b078-8b82707a7eb5Adobe Acrobat 8.216080NCCL100047044089NCCL-71-38112074NCCL093-100-107025NCCL007-115-84055NCCL-113038-80037NCCL-16-107116-16NCCL-63-05-07079NCCL-57074113067NCCL056111104NCCL012-24-98-17NCCL-30-81100090 endstreamendobj1337 0 objendobj5402 0 objendobj170 0 objendobj171 0 objendobj6730 0 objendobj172 0 obj/CM11/CM12/CM13/CM14/CM15/CM16/CM17/CM18/CM19/Normal+1[187 0 R 188…

Fluzone, Fluzone High-Dose and Fluzone Intradermal

<!– –> <!– Page Last Updated: 05/12/2011 –> Page Last Updated: 05/12/2011 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.